Psychedelics: A Breakthrough in Anti-Inflammatory Treatment, A New Era of Therapy

After six decades of prohibition, psychedelics are returning to laboratories and clinics as one of the most promising classes of psychiatric drugs of the 21st century. What was pushed into illegal counterculture in the 1960s is now the subject of rigorous research at Imperial College London, Johns Hopkins, Yale, MAPS, and COMPASS Pathways. In 2024, the global psychedelic therapy market was valued at approximately $5.2 billion, with Grand View Research forecasting growth to over $10 billion by 2030. Interestingly, the latest wave of research indicates that psilocybin, LSD, and tryptamine derivatives not only change the architecture of neural connections but also strongly modulate the immune system, reducing inflammation in the brain and peripheral tissues. In this article, we will trace the history, mechanisms of action, key studies, indications, risks, and the legal status of psychedelics in Poland and the European Union, as well as compare them with cannabis.

What are psychedelics and why are they returning to medicine after 60 years of prohibition?

Psychedelics are a group of psychoactive substances that primarily act as agonists of serotonin receptors 5-HT2A, causing changes in perception, mood, and sense of self. According to data from the Multidisciplinary Association for Psychedelic Studies (MAPS, 2024), the number of active clinical trials involving psilocybin and MDMA exceeded 320 in 2024, compared to fewer than 30 in 2010.

Classic psychedelics include psilocybin (from mushrooms Psilocybe), LSD (lysergic acid diethylamide), DMT/ayahuasca, and mescaline (from the peyote cactus). "Non-classical" substances with similar effects include MDMA (entactogen) and ketamine (dissociative, NMDA antagonist). All modulate neural networks, neuroplasticity, and, as new research shows, the immune system.

Three Waves of Research on Psychedelics

The first wave (1950-1971) resulted in over 1000 publications on LSD. The second wave (prohibition following the 1971 UN Convention) nearly halted research. The third wave, which began around 2006 with the publication of Griffiths' study at Johns Hopkins, led to Breakthrough Therapy statuses granted by the FDA: MDMA-PTSD (2017) and psilocybin-depression (2018, 2019).

Why has the renaissance occurred now?

Three factors are driving the renaissance: the crisis of treatment-resistant depression (TRD affects about 30% of patients treated with SSRIs), the growing epidemic of PTSD among veterans, and the development of neuroimaging (fMRI, MEG), which for the first time allowed us to see how psychedelics "loosen" neural networks, including the Default Mode Network. This has opened a new field of research into therapeutic mechanisms.

What has the history of psychedelic research looked like from Sandoz to the FDA?

The history of clinical research on psychedelics encompasses four distinct phases: the golden era (1950-1965), prohibition (1971+), scientific renaissance (2006+), and regulatory breakthrough (2023-2026). According to archives, MAPS between 1947 and 1965, Sandoz Laboratories produced and sent over 100,000 doses of LSD-25 under the name Delysid to researchers.

1. Golden Era (1950-1965): Sandoz, Hoffer, Osmond, and Leary

Albert Hofmann synthesized LSD in 1938 at Sandoz, and in 1943 discovered its psychoactive effects. In the 1950s, Canadian psychiatrists Humphry Osmond and Abram Hoffer conducted research on LSD in schizophrenia and alcoholism, achieving about 50% lasting abstinence in alcoholics. Osmond coined the term "psychedelic" in 1957. Timothy Leary from Harvard conducted the famous Concord Prison Experiment with psilocybin.

2. Prohibition (1971): UN Convention and Controlled Substances Act

The 1971 UN Convention on Psychotropic Substances placed LSD, psilocybin, mescaline, and DMT in Schedule I, as substances "without recognized medical use." The American Controlled Substances Act of 1970 imposed similar restrictions. The result: nearly complete halt of clinical research for 35 years.

3. Renaissance (2006+): Johns Hopkins, MAPS, Imperial College, COMPASS

Roland Griffiths from Johns Hopkins published a study in 2006 showing that psilocybin induces "mystical experiences" of lasting positive value in 67% of participants. MAPS (founded in 1986 by Rick Doblin) systematically built a dossier on MDMA-PTSD. Imperial College London (Robin Carhart-Harris) was the first to conduct psilocybin studies in treatment-resistant depression (2016). COMPASS Pathways received FDA approval for Phase III studies with synthetic psilocybin COMP360.

4. Breakthrough (2023-2026): Australia, FDA, EMA

In July 2023, Australia became the first country in the world to legalize MDMA for PTSD and psilocybin for treatment-resistant depression in therapeutic settings under psychiatric supervision. In August 2024, the FDA denied registration for MDMA-AT by Lykos Therapeutics, requesting another Phase III study due to methodological concerns (blinding). The EMA is consulting on the regulatory pathway for psilocybin.

What are the main psychedelics used in clinical research?

Six groups of substances dominate current clinical research: psilocybin, MDMA, LSD, ketamine/esketamine, DMT/ayahuasca, and ibogaine. According to the report Psychedelic Alpha (2024), by the end of 2024, over 70% of all active trials involved psilocybin or ketamine. These are the substances closest to registration in the States and Europe.

Psilocybin (Magic Mushrooms): treatment-resistant depression and existential anxiety

Psilocybin is a prodrug that is converted to the active psilocin after administration. It acts as a partial agonist of 5-HT2A. The study by Carhart-Harris et al. (2016) showed that two doses (10 mg and 25 mg) induced remission of depression in 67% of patients after one week and in 42% after three months (Lancet Psychiatry, 2016).

Davis et al. (2021) in a randomized study published in JAMA Psychiatry showed that two doses of psilocybin combined with psychotherapy reduced GRID-HAMD by 22 points in patients with major depression after 4 weeks (Davis et al., JAMA Psychiatry, 2021). COMPASS Pathways is currently conducting Phase III studies COMP005 and COMP006 with synthetic psilocybin.

MDMA: PTSD and assisted therapy

MDMA (3,4-methylenedioxymethamphetamine) acts as a releaser of serotonin, dopamine, and norepinephrine and induces the release of oxytocin. The pivotal trial MAPP1 showed that 67% of patients with severe PTSD did not meet diagnostic criteria after 18 weeks following MDMA-AT.

The expanding MAPP2 study (Mitchell et al., 2023, Nature Medicine) confirmed: 71.2% of patients after MDMA-AT no longer met PTSD criteria vs 47.6% in the placebo group (p<0.001), with a significant reduction in symptom severity (Mitchell et al., Nature Medicine, 2023). Despite these results, the FDA did not register the drug in August 2024.

LSD: anxiety, depression, and cluster headaches

LSD (lysergic acid diethylamide) is the most potent known psychedelic (active dose 50-200 micrograms). Matthias Liechti's Swiss group from the University of Basel conducts systematic research on LSD in generalized anxiety and depression. MindMed (NYSE: MNMD) is conducting Phase II studies on MM-120 (LSD for GAD).

Ketamine and esketamine: rapid response in TRD

Ketamine, an NMDA receptor antagonist, acts within 1-2 hours after administration and maintains its effect for 7-14 days, unlike SSRIs, which require 4-6 weeks. Esketamine (Spravato, Janssen) was registered by the FDA in March 2019 and by the EMA in December 2019 for treatment-resistant depression. Krystal et al. (2024) summarized that sub-anesthetic doses of ketamine reduce depression symptoms in 50-70% of TRD patients after the first infusion (Krystal et al., 2024).

DMT and ayahuasca: rapid experience and social studies

DMT (N,N-dimethyltryptamine) induces a short (10-15 minutes), but extremely intense experience. Ayahuasca is a Brazilian brew containing DMT and a MAO inhibitor (harmine). Research on ayahuasca in depression is being conducted by teams from the Federal University of Rio Grande do Norte. Short tryptamines open the pathway to "fast" psychedelic therapy sessions (<60 min).

Ibogaine: opioid addiction

Ibogaine, an alkaloid from the African plant Tabernanthe iboga, is being studied as an opioid detoxification therapy. According to retrospective studies from Mexican clinics (Brown 2018, MAPS), about 50-60% of patients addicted to opioids achieve long-term abstinence after one ibogaine session. However, the substance has significant risks of cardiotoxicity.

How do psychedelics work at the brain and immune system level?

The mechanism of action of psychedelics includes four pillars: 5-HT2A agonism in the prefrontal cortex, induction of neuroplasticity (psychoplastogens), suppression of the Default Mode Network, and modulation of the immune system. According to a study by Ly et al. (2018) published in Cell Reports, psychedelics increase dendritic spine density by 10-15% within 24 hours after administration (Ly et al., Cell Reports, 2018).

Pillar 1. Agonism of 5-HT2A receptors in the prefrontal cortex

The serotonin receptor 5-HT2A is densely expressed on pyramidal neurons in layer V of the prefrontal cortex. Activation of 5-HT2A by psilocybin, LSD, or DMT increases the excitability of these neurons and the release of glutamate. This, in turn, activates AMPA receptors and the BDNF (brain-derived neurotrophic factor) and mTOR signaling cascade. The 5-HT2A antagonist (ketanserin) blocks the subjective effects of psychedelics.

Pillar 2. Neuroplasticity: psychoplastogens and dendritic growth

The work of Ly et al. (2018) introduced the concept of "psychoplastogens", substances that rapidly and permanently increase neuroplasticity. Psychedelics administered to rats resulted in a 10-15% increase in dendritic spine density in the prefrontal cortex just 24 hours after dosing, with effects lasting over 30 days. This is the structural basis for the "therapeutic window" observed clinically (Ly et al., Cell Reports, 2018).

Pillar 3. Suppression of the Default Mode Network and "ego dissolution"

The Default Mode Network (DMN) is a network of structures (prefrontal cortex, posterior cingulate cortex, precuneus) active at rest, responsible for self-referential thinking. Carhart-Harris et al. demonstrated in fMRI studies that psilocybin and LSD strongly reduce DMN coherence, which correlates with the subjective experience of "ego dissolution" and, clinically, with therapeutic response. Carhart-Harris's REBUS hypothesis links this to a reduction in the brain's "predictive rigidity".

Pillar 4. Anti-inflammatory: 5-HT2A on immune cells

5-HT2A receptors are present not only on neurons but also on immune cells, including monocytes, macrophages, and dendritic cells. The work of Flanagan and Nichols (2018) showed that 5-HT2A agonists, including psilocybin and (R)-DOI, reduce TNF-alpha and IL-6 production and inhibit the expression of adhesion molecules in the endothelium even at sub-behavioral doses (Flanagan & Nichols, 2018).

This opens potential indications for psychedelics in chronic inflammatory, neurodegenerative, and autoimmune diseases. However, it should be emphasized that clinical studies in humans in this direction are just beginning, and current evidence comes mainly from animal models and in vitro.

Which clinical studies from 2023-2026 are the most important?

Four major studies define the current state of clinical evidence: COMPASS Pathways COMP005/006 for psilocybin in TRD, MAPP1/MAPP2 (MAPS) for MDMA-PTSD, Yale studies on ketamine, and a Pittsburgh study on psilocybin in alcoholism. According to ClinicalTrials.gov in 2024, over 320 active trials with psychedelics were registered.

COMPASS Pathways: COMP005/006 (psilocybin TRD)

COMPASS Pathways is conducting two parallel Phase III studies with synthetic psilocybin COMP360 in monotherapy for treatment-resistant depression. COMP005 (data collection completion projected for 2025) compares a single dose of 25 mg vs 1 mg placebo. An earlier Phase II study (Goodwin et al., 2022, NEJM) showed a reduction in MADRS by 6.6 points vs placebo after three weeks, with a lasting effect of 12 weeks in 24% of patients.

MAPP1/MAPP2 (MAPS): MDMA-PTSD

MAPP1 (Mitchell et al., 2021, Nature Medicine) and MAPP2 (Mitchell et al., 2023) are Phase III studies by MAPS Public Benefit Corporation (now Lykos Therapeutics). MAPP2 included 104 patients with moderate to severe PTSD. Result: 71.2% in the MDMA-AT group vs 47.6% in the placebo group did not meet PTSD criteria after 18 weeks (Mitchell et al., 2023).

Yale: ketamine in TRD and suicidality

John Krystal's team at Yale has been studying ketamine in depression for over 20 years. Studies show that intravenous infusion of 0.5 mg/kg reduces SI (suicidal ideation) within 24 hours in 60-70% of patients. Krystal et al. (2024) summarized the state of evidence: ketamine remains an off-label option, while esketamine is an officially registered drug (Krystal et al., 2024).

Bogenschutz (NYU/Pittsburgh): psilocybin in alcoholism

Michael Bogenschutz conducted the first randomized study of psilocybin in alcohol use disorder (AUD) at the University of New Mexico and NYU. 93 patients: two psilocybin sessions + psychotherapy vs active placebo (diphenhydramine). Result: reduction of "heavy drinking days" from 52.7% to 9.7% in the psilocybin group vs a decrease to 23.6% in the placebo group (Bogenschutz et al., JAMA Psychiatry, 2022).

What are the therapeutic indications for psychedelics?

Five main indications have the strongest clinical evidence: treatment-resistant depression (TRD), PTSD, existential anxiety in terminal illnesses, addictions (alcohol, nicotine, opioids), and potentially chronic inflammatory diseases. According to a meta-analysis by Goldberg et al. (2020), psilocybin therapy reduces depression symptoms by an effect size of Hedges g = 1.17 vs active placebo.

1. Treatment-resistant depression (TRD)

Definition of TRD: lack of response to at least two courses of SSRIs/SNRIs at appropriate doses. It affects about 30% of patients with major depression. Psilocybin and ketamine show efficacy where SSRIs fail, acting quickly (from 1 day for ketamine, from a few days for psilocybin), with effects lasting weeks to months.

2. PTSD in combat veterans and victims of violence

Remission rate after MDMA-AT: 67-71% vs 26-48% placebo. This is about 2x better than the current standard (CBT, EMDR, sertraline, paroxetine). MDMA helps to "process" traumatic memories without overwhelming anxiety, due to the release of oxytocin and reduced amygdala reactivity.

3. Existential anxiety in terminal cancer

Two randomized studies (Griffiths 2016, Ross 2016) showed that a single dose of psilocybin 22-30 mg reduces existential anxiety and depression in patients with advanced cancer by 60-80% for over 6 months. These are some of the strongest effects observed in psychiatry.

4. Addictions: alcohol, nicotine, opioids

Bogenschutz (2022): reduction of heavy drinking days by over 80%. Johnson (2014): psilocybin in nicotine withdrawal resulted in 80% abstinence after 6 months (vs ~35% for standard therapies). Ibogaine: studied in opioids, but serious cardiological risks limit its use.

5. Potential anti-inflammatory effects in chronic diseases

Nichols' hypothesis: low, sub-behavioral doses of psychedelics (DOI, psilocybin) may act as selective immunomodulators without psychoactive effects. Potential indications: Crohn's disease, psoriasis, RA, atherosclerosis, Alzheimer's disease. Human studies in this direction are just starting.

What are the risks and contraindications of psychedelic therapy?

Five main areas of risk: psychotic predispositions, "bad trip" and post-session anxiety, HPPD (Hallucinogen Persisting Perception Disorder), interactions with SSRIs (serotonin syndrome), and impairment of motor functions. According to Strassman's review (1984), psychotic reactions after LSD in uncontrolled conditions occur in about 0.08-4.6 per 1000 people.

Psychotic risk and exclusions in trials

Classic psychedelics can induce or reveal psychosis in predisposed individuals (personal or family history of schizophrenia, bipolar disorder type I). All clinical trials exclude such patients. Absolute contraindication: first-degree relatives with schizophrenia.

"Bad trip" and psychotherapeutic support

A difficult experience ("challenging experience") may occur in 20-30% of trial participants. In a clinical context, with the appropriate set, setting, and therapist support, the risk of traumatization is minimal. Carbonaro et al. (2016) showed that even among respondents in non-therapeutic surveys, 84% retrospectively rated a "bad trip" as a ultimately positive experience.

HPPD (Hallucinogen Persisting Perception Disorder)

HPPD is a rare disorder characterized by persistent visual perception disturbances (tracers, halos, minor aberrations) after using psychedelics. Frequency: estimates range from 1:50,000 to 1:5,000 exposures. In clinical trials with pure substances and controlled doses, HPPD is extremely rare.

Interactions with SSRIs: serotonin syndrome

Combining classic psychedelics with SSRIs/SNRIs or MAOIs can trigger serotonin syndrome (fever, muscle rigidity, seizures, death). All clinical protocols require discontinuation of serotonergic medications 2-6 weeks before the session. Ketamine, acting on NMDA, is safer in this regard.

Driving safety

After a psychedelic session, one should not drive for at least 24 hours. Most protocols require that the patient has a companion to pick them up from the clinic. Intravenous ketamine: driving ban for 12-24 hours after infusion.

What is the legal status of psychedelics in Poland and the EU in 2026?

Poland classifies psilocybin, LSD, MDMA, DMT, and mescaline as substances in group I-P (highest restriction) in the annex to the Act of July 29, 2005, on Counteracting Drug Addiction (ISAP, Journal of Laws 2005 No. 179 item 1485). Possession and trafficking are punishable (penalty from 1 month to 10 years of imprisonment).

What exceptions are available in Poland?

Esketamine (Spravato) registered by the EMA in 2019 is available in some Polish psychiatric hospitals for treatment-resistant depression. Intravenous ketamine is used off-label in selected private clinics. Classic psychedelics (psilocybin, LSD, MDMA) are also unavailable in clinical trials in Poland, although individual centers are considering participation in European trials.

Germany, Czech Republic, Netherlands, Switzerland: access pathways

Germany plans to expand early access programs for psilocybin in TRD in 2026. The Czech Republic has had a Center for Psychedelic Studies at Charles University in Prague since 2020, conducting trials with psilocybin. Switzerland maintains a "compassionate use" program allowing psychiatrists to apply for a license for psilocybin and MDMA for specific patients (since 2014).

EMA pathway: when will psilocybin reach Europe?

The EMA is consulting on a guide for clinical research with psychedelics (Reflection Paper 2024). COMPASS Pathways and atai Life Sciences plan to submit registration applications to the EMA in 2026-2027. The realistic timeline for the first registration in the EU: 2027-2029.

How do psychedelics differ from cannabis and CBD?

Psychedelics and cannabis act on completely different receptor systems: psychedelics on 5-HT2A (serotonergic), cannabinoids on CB1/CB2 (endocannabinoid). However, they surprisingly share similar end effects: neuroplasticity, anti-inflammatory effects, and modulation of the Default Mode Network. According to Babson et al. (2017), about 18% of medical marijuana users use it for anxiety, and 25% for chronic pain.

Mechanism: serotonergic vs endocannabinoid

Psilocybin, LSD, and DMT act as agonists of 5-HT2A. THC is a partial agonist of CB1 (psychoactive effect) and CB2 (anti-inflammatory effect). CBD does not strongly bind to CB1, primarily acting allosterically and on 5-HT1A, TRPV1, GPR55, PPAR-gamma receptors. CBD is non-psychoactive and does not induce hallucinations.

Common features: anti-inflammatory and neuroplasticity

Both cannabinoids and psychedelics reduce inflammatory markers (TNF-alpha, IL-6, IL-1beta), although through different pathways. Both groups increase BDNF and support neuroplasticity. Both modulate the DMN, although psychedelics do so more strongly. This opens the discussion on combined therapies in the future.

Indications: partial overlap

Cannabis: chronic pain, spasticity (MS), treatment-resistant epilepsy (Dravet, Lennox-Gastaut), chemotherapy-induced nausea, anorexia in AIDS/cancer. Psychedelics: TRD, PTSD, existential anxiety, addictions. Common potential field: anxiety, sleep disorders, inflammatory diseases of the nervous system.

Legal status in Poland: diverging paths

Cannabis CBD <0.3% THC: legal (cosmetics, supplements, dried flowers). Medical marijuana with THC: available by prescription since 2017. Classic psychedelics: illegal, no medical pathway. Esketamine: available in psychiatric hospitals.

What’s next? The coming years of psychedelic therapy in Europe

Three scenarios define the future: rapid registration by the EMA (2027-2029), expansion of early access programs in Germany, the Czech Republic, and Switzerland, and the establishment of specialized psychedelic centers under psychiatric supervision. According to forecasts, Grand View Research (2024) the global psychedelic therapy market will reach $10.75 billion by 2030.

What does this mean for patients in Poland?

Short-term (2026-2027): no significant changes, access only to esketamine in selected hospitals. Medium-term (2028-2030): potential registration of psilocybin by the EMA, possible import for selected centers. Long-term (2030+): possible Polish legislation following the path of Germany or the Netherlands.

How to choose an informed direction for education?

We recommend Polish patients interested in the topic to consult with a psychiatrist (especially academic centers in Warsaw, Krakow, and Poznan, where research on ketamine is conducted), follow publications from MAPS, COMPASS Pathways, and the Imperial College Centre for Psychedelic Research, and be cautious of offers for "therapeutic trips" to liberal countries that often lack sufficient medical standards.

FAQ: Frequently Asked Questions about psychedelic therapy

1. Is psilocybin legal in Poland in 2026?

No. Psilocybin and mushrooms Psilocybe are illegal in Poland under the Act of July 29, 2005, on Counteracting Drug Addiction (substance group I-P). Possession and trafficking are punishable (from 1 month to 10 years of imprisonment). Psilocybin is currently not available in clinical trials in Poland, although consultations on the EMA pathway are ongoing.

2. How does ketamine therapy work in treatment-resistant depression?

Ketamine, an NMDA antagonist, administered at a sub-anesthetic dose (0.5 mg/kg intravenously) acts within 1-2 hours and reduces depression symptoms in 50-70% of TRD patients (Krystal et al., 2024). Esketamine (Spravato), the nasal form, is officially registered by the FDA and EMA. The effect lasts 7-14 days, which is why therapy involves a series of infusions.

3. Does MDMA really treat PTSD?

The pivotal MAPP2 study (Mitchell et al., 2023, Nature Medicine) showed that 71.2% of patients after MDMA-AT no longer met PTSD diagnostic criteria vs 47.6% in the placebo group. Despite this, the FDA in August 2024 denied registration for Lykos Therapeutics, requesting an additional Phase III study due to methodological concerns regarding blinding.

4. What are psychoplastogens?

Psychoplastogens are substances that rapidly and durably increase neuroplasticity, including increased dendritic spine density and synaptogenesis. The term was introduced by Ly et al. (2018, Cell Reports). Classic psychedelics (psilocybin, LSD, DMT, MDMA) are classic psychoplastogens, as is ketamine, although it operates through a different mechanism (NMDA).

5. Do psychedelics really have anti-inflammatory effects?

In in vitro and animal models, yes. Flanagan and Nichols (2018) demonstrated that 5-HT2A agonists reduce TNF-alpha, IL-6, and the expression of adhesion molecules. 5-HT2A receptors are present on monocytes, macrophages, and dendritic cells. Clinical studies in this direction are at a very early stage, and there is currently no registration for any inflammatory indication.

6. What is a "bad trip" and how often does it occur in clinical trials?

"Bad trip" (challenging experience) is a difficult emotional experience during a psychedelic session, involving anxiety, paranoia, dysphoric visions. In clinical trials with the appropriate set and setting, it occurs in 20-30% of participants, but Carbonaro et al. (2016) showed that 84% retrospectively rated it as ultimately positive. In uncontrolled conditions, the risk of trauma significantly increases.

7. Can psychedelics be combined with SSRIs or SNRIs?

Not without medical supervision. Combining classic psychedelics with SSRIs/SNRIs/MAOIs risks serotonin syndrome (fever, muscle rigidity, seizures, risk of death). All clinical protocols require discontinuation of serotonergic medications 2-6 weeks before the session. Ketamine (NMDA) is safer in this regard but requires psychiatric consultation.

8. How does psilocybin differ from CBD?

These are completely different compounds. Psilocybin: tryptamine, 5-HT2A agonist, highly psychoactive, requires a therapeutic session, illegal in Poland. CBD: cannabinoid, primarily acts on 5-HT1A, TRPV1, PPAR-gamma, non-psychoactive, legal in Poland with <0.3% THC. Common features: both have anti-inflammatory and anxiolytic potential, but through different receptor pathways.

9. How much does psilocybin therapy cost abroad?

In the Netherlands (truffle retreats, legally gray): from 1500 to 5000 EUR for a weekend with 1-2 sessions. In Switzerland (compassionate use, legal): 10,000-25,000 CHF for a full program. In the States (Oregon, Colorado, state programs): 2000-5000 USD per session. These are out-of-pocket offers allowing the use of classic psychedelics only in selected jurisdictions.

10. When will psilocybin be available in Poland?

Realistic timeline: 2028-2030, if the EMA registers psilocybin from COMPASS Pathways (COMP360). COMPASS plans to submit a registration application in 2026-2027. After EMA registration, the Polish Office for Registration of Medicinal Products must approve the import. Germany and the Netherlands will likely be the first in the EU.

Summary: a new era of psychiatry cautiously returns to the mainstream

Psychedelics, after 60 years of prohibition, are returning to medicine in an unprecedented way: as fast-acting drugs, with lasting effects after a single dose and potentially broad indications: from treatment-resistant depression, through PTSD, existential anxiety, addictions, to chronic inflammatory diseases. The mechanism of action, 5-HT2A agonism, induction of neuroplasticity, suppression of DMN, and immunological modulation, is unique and difficult to replicate with other classes of drugs.

Poland remains in 2026 a country with restrictive legislation: psilocybin, LSD, MDMA, and DMT are illegal, only esketamine (Spravato) and off-label ketamine provide Polish patients with TRD access to a "psychedelic" therapeutic pathway. Germany, the Czech Republic, and Switzerland are at the forefront in Europe. Real registration of psilocybin by EMA: 2027-2029.

If you are struggling with treatment-resistant depression, PTSD, or anxiety, first consult a psychiatrist. Do not attempt self-therapy with illegal substances; the legal, health, and psychological risks are real. Follow scientific publications, COMPASS Pathways, MAPS, and the Imperial College Centre for Psychedelic Research to stay informed. And if you are interested in legal support pathways for anxiety, sleep, or chronic pain, check out the CBD product offerings that act on a different but also strongly modulating endocannabinoid system.

Recommended CBD products from the u Bucha offer